Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,411.20
(
-2.35%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,114.40
(
-0.34%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122816
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mblimon post# 3266

Thursday, 04/12/2007 5:39:58 PM

Thursday, April 12, 2007 5:39:58 PM

Post# of 19309
>Was so little known about safety limits before?<

Merrimack is evidently surprised that MM-093 has shown essentially no side effects. In dose-finding studies, it’s a heck of a lot better to start too low than to start too high and run into a clinical hold.

If Merrimack manages to find a dose that is both safe and effective, MM-093 has blockbuster potential (IMO) as a second-line treatment for RA following failure on one of the TNF-a drugs. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today